Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences Ltd has shown promising financial dynamics, particularly with the recent raise in revenue estimates for the drug candidate IMVT-1402, which demonstrates its strategic positioning in the competitive landscape of Graves' disease treatment. The successful results from the Phase 3 VALOR study of brepocitinib further enhance investor confidence, highlighting its efficacy in treating dermatomyositis (DM) compared to traditional therapies, which could significantly expand market share in this space. Additionally, the unique value proposition of Batoclimab as the first clinical candidate with potential disease-modifying effects reinforces Roivant’s innovative edge in addressing high-unmet medical needs.

Bears say

The financial outlook for Roivant Sciences Ltd appears negative primarily due to the repeated failures of several key drug candidates in clinical trials, including brepocitinib, which failed to demonstrate efficacy in multiple indications such as dermatomyositis and non-infectious uveitis. Additionally, concerns have been raised about the potential off-target effects of treatments being developed, which may hinder their overall safety and market viability. Overall, the combination of these trial failures and safety concerns highlight significant risks that could adversely affect Roivant's future revenue generation capabilities, casting doubt on the company’s growth prospects in the competitive biopharmaceutical landscape.

ROIV has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 8 analysts, ROIV has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.